Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug intolerance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    578 result(s) found for: Drug intolerance. Displaying page 1 of 29.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004889-18 Sponsor Protocol Number: 1.3 Start Date*: 2022-04-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab in patients with aspirin-exacerbated respiratory disease (AERD) -A single-center prospective pilot study
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad or Widal's triad, comprises the triad of allergic asthma, chronic rhinosinusitis with nasal polyps (CRswNP) and nonstero...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003119-21 Sponsor Protocol Number: 1 Start Date*: 2017-12-22
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Omalizumab in patients with Aspirin-Exazerbated Respiratory Disease (AERD)
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or Widal's triad, comprises the triad of Asthma, chronic rhinosinusitis with nasal polyps (CRwNP) and nonsteroidal anti-...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002537-41 Sponsor Protocol Number: 20170104 Start Date*: 2022-01-06
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Sev...
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) RO (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002795-41 Sponsor Protocol Number: B1481038 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) SK (Prematurely Ended) ES (Completed) BE (Prematurely Ended) DK (Completed) SE (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004130-24 Sponsor Protocol Number: M15-572 Start Date*: 2017-07-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at ...
    Medical condition: Moderately to Severely Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) NL (Completed) PT (Completed) EE (Completed) LV (Completed) LT (Completed) SI (Completed) HU (Completed) ES (Ongoing) HR (Completed) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006881-19 Sponsor Protocol Number: TV48574-IMM-20036 Start Date*: 2022-12-21
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerat...
    Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.0 100000004856 10011400 Crohn's colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002782-32 Sponsor Protocol Number: C13006 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative C...
    Medical condition: Moderate to Severe Ulcerative Colitis Colitis ulcerosa moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) DK (Completed) IS (Completed) PT (Prematurely Ended) BE (Completed) FR (Completed) GB (Completed) BG (Completed) IT (Completed) MT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004323-37 Sponsor Protocol Number: BOS-IIG-01 Start Date*: 2015-03-24
    Sponsor Name:Fundación PETHEMA para el tratamiento de la leucemia y el linfoma
    Full Title: Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment.
    Medical condition: Patients with chromosome Philadelphia positive (Ph+) in chronic phase mielogenus leukemia (CP CML)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003604-19 Sponsor Protocol Number: IM101108 Start Date*: 2007-08-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative C...
    Medical condition: ULCERATIVE COLITIS,NOS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IE (Prematurely Ended) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001199-12 Sponsor Protocol Number: MLN0002/CCT-001 Start Date*: 2019-05-28
    Sponsor Name:Takeda
    Full Title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induct...
    Medical condition: This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous Vedolizumab (300 mg) infusi...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001198-10 Sponsor Protocol Number: MLN0002/CCT-101 Start Date*: 2019-05-28
    Sponsor Name:Takeda
    Full Title: A Phase 3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induc...
    Medical condition: The purpose of the trial is to examine the efficacy, safety, and pharmacokinetics of intravenous Vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese patients with moderat...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018708-99 Sponsor Protocol Number: 1245.39 Start Date*: 2010-10-19
    Sponsor Name:BOEHRINGER ING.
    Full Title: An open-label, phase IIb study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor ...
    Medical condition: patients with IGT or type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 LLT
    9.1 10018429 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002783-33 Sponsor Protocol Number: C13007 Start Date*: 2009-03-02
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn?s Dise...
    Medical condition: Moderate to Severe Crohn's Disease Enfermedad de Crohn moderada o grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) HU (Completed) SK (Completed) AT (Completed) IE (Completed) LV (Completed) CZ (Completed) NL (Completed) IS (Completed) PT (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) MT (Completed) GB (Completed) BG (Completed) SE (Completed) IT (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003335-35 Sponsor Protocol Number: M13-542 Start Date*: 2016-05-03
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately ...
    Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) ES (Completed) DK (Completed) CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NO (Completed) SK (Completed) PT (Completed) LV (Completed) AT (Completed) FI (Completed) GR (Completed) FR (Completed) BG (Completed) SI (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003371-13 Sponsor Protocol Number: IM101084 Start Date*: 2007-07-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Diseas...
    Medical condition: Crohn's disease, NOS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011401 Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Prematurely Ended) GB (Prematurely Ended) BE (Completed) IE (Completed) DK (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2017-003206-41 Sponsor Protocol Number: TAK-954-2002 Start Date*: 2018-05-29
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Int...
    Medical condition: A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Int...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10074293 Enteral feeding intolerance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003450-28 Sponsor Protocol Number: CL009_282 Start Date*: 2007-09-04
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease
    Medical condition: Celiac Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-002027-16 Sponsor Protocol Number: RPCG06B2433 Start Date*: 2006-12-12
    Sponsor Name:UCB AE
    Full Title: Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subseq...
    Medical condition: Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000431-14 Sponsor Protocol Number: M16-098 Start Date*: 2017-11-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis
    Medical condition: Active Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DK (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PT (Completed) NL (Completed) BE (Completed) HU (Completed) PL (Completed) SE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002465-22 Sponsor Protocol Number: M16-011 Start Date*: 2018-12-11
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Leas...
    Medical condition: Psoriatic Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Trial now transitioned) NL (Ongoing) LT (Trial now transitioned) PT (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SI (Completed) SK (Trial now transitioned) HR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 11:24:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA